chimeric NKG2D T cells

Chimeric NKG2D T cells are genetically engineered T cells that express a chimeric antigen receptor (CAR) based on the activating immunoreceptor NKG2D, designed to specifically recognize ligands frequently expressed on malignant or stressed cells but largely absent from healthy tissue. These cells combine an extracellular NKG2D domain for ligand recognition with intracellular signaling domains (most often CD3ζ and costimulatory motifs such as Dap10 or Dap12), allowing potent and selective cytolytic activity against various tumors including solid and hematologic malignancies. Preclinical models and early-phase clinical trials have demonstrated high tumor specificity, robust antitumor efficacy, and low off-tumor toxicity in indications such as esophageal squamous cell carcinoma, glioblastoma, gastric cancer, colorectal cancer, ovarian cancer, and other NKG2D ligand-positive tumors. Chimeric NKG2D T cells are being developed as next-generation cell therapies to overcome immunosuppression in the tumor microenvironment and broaden the applicability of CAR-T-based immunotherapy to solid tumors[1][2][3][4][5].

Other names

chNKG2D T cellschNKG-2D T cellschNKG 2D T cellsNKG2D CAR-T cellsNKG-2D CAR-T cellsNKG 2D CAR-T cellsNKG2D chimeric antigen receptor T cellsNKG-2D chimeric antigen receptor T cellsNKG 2D chimeric antigen receptor T cellsNKG2D/Dap10-12 T cellsKD-025KD025KD 025